In recent years, there has been increased awareness regarding differentiating MS from other demyelinating ON phenotypes, namely, neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This evidence concerns the gene MOG and myeloid sarcoma.